**Key Clinical Data to Be Revealed Soon** Biopharmaceutical company Alumis Inc. announced that the phase III clinical trial data of its lead candidate drug Envudeucitinib for the treatment of moderate-to-severe plaque psoriasis has been selected for the "Late-Breaking Breakthroughs" oral presentation session at the 2026 American Academy of Dermatology (AAD) Annual Meeting.

Key Clinical Data to Be Revealed Soon Biopharmaceutical company Alumis Inc. announced that the phase III clinical trial data of its lead candidate drug Envudeucitinib for the treatment of moderate-to-severe plaque psoriasis has been selected for the "Late-Breaking Breakthroughs" oral presentation session at the 2026 American Academy of Dermatology (AAD) Annual Meeting.

老虎证券2026/03/18 12:26

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This section specifically showcases the latest research results with high clinical value, indicating that the phase III data of Envudeucitinib has been recognized by the academic committee for its scientific significance. **Psoriasis Market Landscape and Competitive Potential** Plaque psoriasis, as an autoimmune skin disease, has a large global patient population. Although there are many existing treatment options, there are still unmet clinical needs. Envudeucitinib is an oral TYK2 inhibitor whose mechanism of action targets specific points in the JAK-STAT signaling pathway, theoretically offering a better balance between efficacy and safety. If the phase III data is positive, this drug is expected to submit a marketing application around the 2026 AAD Annual Meeting, entering the sizable psoriasis treatment market. **Subsequent Development and Market Impact** Alumis plans to announce detailed efficacy and safety results from the phase III trial of Envudeucitinib at the 2026 AAD Annual Meeting. These data will have a direct impact on the company's valuation and may attract acquisition interest from major pharmaceutical companies. The investment community will closely monitor the drug's performance in efficacy indicators (such as PASI 75/90/100 response rates) and safety characteristics (especially risks such as infection and elevated liver enzymes) to assess its market competitiveness.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

October 9 - ** Shares of Australian Maas Group (MGH.AX) have fallen more than 27% so far this week and are set for their worst weekly performance if the downward trend continues. ** On Thursday, media reported that Firmus, backed by Nvidia, might reduce the size of its AUD 5 billion Australian IPO (link), sparking investor concerns and leading to a 30% plunge in shares of construction services provider MGH. ** MGH holds a 3.2% stake in this AI data center operator. ** MGH suspended trading on Friday (link), pending an announcement related to Firmus. Firmus has shelved its AUD 5 billion listing plan due to market volatility and conditions. ** Before the suspension, MGH's shares had already fallen over 8% this year. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. This automated translation may contain inaccuracies or omit the desired context; Reuters does not guarantee the accuracy of automated translations and provides them solely for reader convenience. Reuters accepts no liability for any harm or loss caused by the use of automated translations.)

路透社•2026/10/09 01:26

Apple to launch dual products in October: First touch-screen MacBook and new iPad mini to debut simultaneously

Apple is planning to hold its second product launch event of the month around October 27, where it will introduce its first-ever touchscreen MacBook Pro (featuring an OLED display and the “Dynamic Island” interface), a new iPad mini (also upgraded with OLED and a repositioned camera), as well as a 14-inch MacBook Pro and iMac powered by the M6 chip. These are the first major products overseen by the new CEO, John Ternus.

华尔街见闻•2026/10/09 01:01